2023
Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Gavrielatou N, Vathiotis I, Aung T, Shafi S, Burela S, Fernandez A, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm D. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Research Communications 2023, 3: 558-563. PMID: 37057033, PMCID: PMC10088911, DOI: 10.1158/2767-9764.crc-22-0299.Peer-Reviewed Original ResearchMeSH KeywordsCarcinomaHead and Neck NeoplasmsHumansImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckConceptsDigital spatial profilingB2M expressionOverall survivalM HNSCCImmunotherapy outcomesNeck squamous cell carcinoma (HNSCC) treatmentHigh beta-2 microglobulinSquamous cell carcinoma treatmentCell death protein 1Neck squamous cell carcinomaM expressionPretreatment biopsy samplesImmune checkpoint inhibitorsPD-L1 expressionImmune checkpoint markersDeath protein 1Squamous cell carcinomaB2MBeta-2-microglobulinBeta 2 microglobulin expressionImproved PFSCheckpoint inhibitorsMetastatic headCheckpoint markersImproved survival
2022
Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms
Aung TN, Shafi S, Wilmott JS, Nourmohammadi S, Vathiotis I, Gavrielatou N, Fernandez A, Yaghoobi V, Sinnberg T, Amaral T, Ikenberg K, Khosrotehrani K, Osman I, Acs B, Bai Y, Martinez-Morilla S, Moutafi M, Thompson JF, Scolyer RA, Rimm DL. Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms. EBioMedicine 2022, 82: 104143. PMID: 35810563, PMCID: PMC9272337, DOI: 10.1016/j.ebiom.2022.104143.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsHumansLymphocytes, Tumor-InfiltratingMachine LearningMelanomaNeoplasm Recurrence, LocalPrognosisProspective StudiesSkin NeoplasmsConceptsTumor-infiltrating lymphocytesMelanoma patientsPrognostic valuePrognostic markerPrimary melanoma patientsRobust prognostic markerStage II patientsSpecific molecular subtypesTIL phenotypeAdjuvant therapyOverall survivalSurgical treatmentTIL scoreII patientsSurvival outcomesLung cancerClinical trialsPrimary melanomaClinical impactT cellsMolecular subtypesHigh riskIndependent cohortLower riskEosin staining